Video Content Compliance Monitor

Continuous FDA regulatory compliance monitoring for promotional video content

Configure Alerts How It Works
Monitoring Active
Last FDA Check: May 22, 2026
Algorithm: v3.2 (14 patterns from 42 letters)
Brands Monitored: 43
43
Total Assets
28
Active Alerts
65
Avg Score
9
At Risk
19
Caution
2
Lower Risk

Portfolio Risk Map

At Risk
Velsipity (58)58Fasenra (57)57Jublia (54)54Qulipta (60)60Attruby (60)60BRUKINSA (58)58FABHALTA (60)60Sotyktu (54)54Cosentyx (59)59
Caution
Calquence (67)67Jardiance (64)64Contrave (63)63Farxiga (66)66Austedo XR (69)69Camzyos (62)62Kesimpta (64)64Linzess (65)65Ingrezza (63)63COBENFY (68)68Vyvgart Hytrulo (gMG) (75)75Vyvgart Hytrulo (CIDP) (61)61Neffy (62)62Wegovy Pill (72)72TREMFYA (70)70Dupixent (63)63Keytruda (67)67Eliquis (74)74Rinvoq (65)65
Lower Risk
Trelegy Ellipta (79)79BRUKINSA (Bridge Walker) (87)87

Compliance Risk Drivers

Average dimension scores across portfolio (lower = higher risk)

Visual Distraction
50
50
Efficacy
69
69
Fair Balance
70
70
Adequate Provision
88
88
Content Lifecycle
30
30
Portfolio Brands
Calquence
AstraZeneca Pharmaceuticals LP
67
Caution 5 patterns Visual Distraction FDA Letter
DOC-2025-001234
Jardiance
Boehringer Ingelheim Pharmaceuticals
64
Caution 4 patterns Visual Distraction FDA Letter
DOC-2025-001245
Velsipity
Pfizer
58
At Risk 4 patterns Visual Distraction FDA Letter
DOC-2025-001236
Contrave
Currax Pharmaceuticals
63
Caution 4 patterns Visual Distraction FDA Letter
DOC-2025-001237
Farxiga
AstraZeneca Pharmaceuticals LP
66
Caution 4 patterns Visual Distraction FDA Letter
Austedo XR
Teva Pharmaceuticals
69
Caution 3 patterns Fair Balance FDA Letter
DOC-2025-001238
Camzyos
Bristol Myers Squibb
62
Caution 2 patterns Visual Distraction FDA Letter
DOC-2025-001239
Kesimpta
Novartis
64
Caution 6 patterns Visual Distraction FDA Letter
DOC-2025-001247
Fasenra
AstraZeneca
57
At Risk 5 patterns Visual Distraction FDA Letter
DOC-2025-001243
Linzess
AbbVie/Ironwood
65
Caution 5 patterns Visual Distraction FDA Letter
DOC-2025-001241
Jublia
Bausch Health
54
At Risk 6 patterns Visual Distraction FDA Letter
DOC-2025-001235
Qulipta
AbbVie
60
At Risk 2 patterns Visual Distraction FDA Letter
DOC-2025-001242
Ingrezza
Neurocrine Biosciences
63
Caution 3 patterns Visual Distraction FDA Letter
DOC-2025-001246
Attruby
Alnylam Pharmaceuticals
60
At Risk 6 patterns Visual Distraction FDA Letter
DOC-2025-001244
COBENFY
Karuna Therapeutics (Bristol Myers Squibb)
68
Caution 3 patterns Visual Distraction FDA Letter
BRUKINSA
BeiGene (BeOne Medicines)
58
At Risk 4 patterns Visual Distraction FDA Letter
NEXLIZET
Esperion Therapeutics, Inc.
0
Pending FDA Letter
Vyvgart Hytrulo (gMG)
argenx
75
Caution 2 patterns Visual Distraction FDA Letter
Vyvgart Hytrulo (CIDP)
argenx
61
Caution 3 patterns Visual Distraction FDA Letter
Neffy
ARS Pharmaceuticals
62
Caution 2 patterns Visual Distraction FDA Letter
Wegovy Pill
Novo Nordisk
72
Caution 2 patterns Visual Distraction FDA Letter
TREMFYA
Janssen Biotech (Johnson & Johnson)
70
Caution 4 patterns Visual Distraction FDA Letter
FABHALTA
Novartis Pharmaceuticals
60
At Risk 5 patterns Visual Distraction FDA Letter
Dupixent
Sanofi/Regeneron
63
Caution 6 patterns Visual Distraction
Keytruda
Merck
67
Caution 5 patterns Visual Distraction
Eliquis
BMS/Pfizer
74
Caution 3 patterns Visual Distraction
Rinvoq
AbbVie
65
Caution 4 patterns Visual Distraction
Trelegy Ellipta
GSK
79
Lower Risk 2 patterns Visual Distraction
Sotyktu
BMS
54
At Risk 6 patterns Visual Distraction
Cosentyx
Novartis
59
At Risk 6 patterns Visual Distraction
ADCETRIS
Pfizer, Inc.
null
Pending FDA Letter
BRUKINSA (Bridge Walker)
BeOne Medicines USA
87
Lower Risk
LUCEMYRA
BioCorRx Pharmaceuticals Inc.
null
Pending FDA Letter
ALYMSYS
Amneal Pharmaceuticals LLC
null
Pending FDA Letter
NIKTIMVO
Incyte Corporation
null
Pending FDA Letter
AMVUTTRA
Alnylam Pharmaceuticals, Inc.
null
Pending FDA Letter
NUBEQA
Bayer HealthCare Pharmaceuticals, Inc.
null
Pending FDA Letter
TURALIO
Daiichi Sankyo, Inc.
null
Pending FDA Letter
TEVIMBRA
BeOne Medicines USA, Inc.
null
Pending FDA Letter
ANKTIVA
Altor BioScience, LLC (ImmunityBio)
null
Pending FDA Letter
XCOPRI
SK Life Science, Inc.
null
Pending FDA Letter
Vonjo
Swedish Orphan Biovitrum (Sobi)
null
Pending FDA Letter
Ozempic
Novo Nordisk Inc.
null
Pending FDA Letter

Powered by cQuenced